MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Allogene Therapeutics Inc

Fechado

SetorSaúde

1.44 5.11

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.41

Máximo

1.45

Indicadores-chave

By Trading Economics

Rendimento

6.4M

-60M

EPS

-0.28

Funcionários

226

EBITDA

6.8M

-56M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+490.28% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-120M

337M

Abertura anterior

-3.67

Fecho anterior

1.44

Sentimento de Notícias

By Acuity

50%

50%

167 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Allogene Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de abr. de 2025, 22:38 UTC

Ações em Alta

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 de abr. de 2025, 21:53 UTC

Conversa de Mercado

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 de abr. de 2025, 21:44 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 de abr. de 2025, 21:00 UTC

Principais Notícias

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 de abr. de 2025, 20:52 UTC

Conversa de Mercado

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 de abr. de 2025, 20:52 UTC

Principais Notícias

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de abr. de 2025, 20:48 UTC

Principais Notícias

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 de abr. de 2025, 20:45 UTC

Principais Notícias

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 de abr. de 2025, 20:32 UTC

Principais Notícias

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 de abr. de 2025, 20:21 UTC

Principais Notícias

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 de abr. de 2025, 20:00 UTC

Principais Notícias

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 de abr. de 2025, 19:51 UTC

Conversa de Mercado

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 de abr. de 2025, 19:37 UTC

Principais Notícias

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 de abr. de 2025, 19:32 UTC

Conversa de Mercado

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 de abr. de 2025, 19:28 UTC

Principais Notícias

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 de abr. de 2025, 19:15 UTC

Conversa de Mercado

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 de abr. de 2025, 19:12 UTC

Principais Notícias

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 de abr. de 2025, 19:11 UTC

Conversa de Mercado

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 de abr. de 2025, 19:09 UTC

Conversa de Mercado

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 de abr. de 2025, 19:09 UTC

Principais Notícias

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 de abr. de 2025, 19:00 UTC

Conversa de Mercado

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 de abr. de 2025, 18:53 UTC

Conversa de Mercado

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 de abr. de 2025, 18:51 UTC

Conversa de Mercado

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 de abr. de 2025, 18:44 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 de abr. de 2025, 18:44 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de abr. de 2025, 18:44 UTC

Conversa de Mercado

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 de abr. de 2025, 18:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 de abr. de 2025, 18:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 de abr. de 2025, 18:39 UTC

Conversa de Mercado

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Comparação entre Pares

Variação de preço

Allogene Therapeutics Inc Previsão

Preço-alvo

By TipRanks

490.28% parte superior

Previsão para 12 meses

Média 8.5 USD  490.28%

Máximo 14 USD

Mínimo 4 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Allogene Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

11

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.3 / 1.45Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

167 / 386 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.